Naglazyme Market Report 2026

Naglazyme Market Overview

• The Naglazyme market growth in the historic period has been driven by improved diagnosis of lysosomal storage disorders, expansion of rare disease awareness programs • Market expansion is supported by growing investments in rare disease research, rising demand for long-term therapeutic solutions • Growth Driver: Increasing Incidence Of Rare Genetic Disorders Fuels Growth Of The Market • North America was the largest region in 2025.

What Is Covered Under Naglazyme Market?

Naglazyme (galsulfase) is an enzyme replacement therapy used to treat mucopolysaccharidosis VI (MPS VI), also known as Maroteaux-Lamy syndrome. It works by supplementing the missing or deficient enzyme, helping to reduce the accumulation of glycosaminoglycans (GAGs) and alleviate some of the symptoms of the disease. It is administered via intravenous infusion, typically under the supervision of a healthcare provider with experience in managing MPS conditions. The main indication for naglazyme is the treatment of maroteaux-lamy syndrome and other rare lysosomal storage disorders. Maroteaux lamy syndrome is a rare genetic disorder caused by the lack of the enzyme arylsulfatase B. The treatment is suitable for both pediatric and adult patients and is distributed through various distribution channels such as hospital pharmacies, specialty pharmacies, retail pharmacies, online pharmacies, as well as government and public health programs. These are also used for various end users such as hospitals, specialty clinics, research institutions, and homecare settings.

What Is The Naglazyme Market Growth Forecast?

The growth in the forecast period can be attributed to growing investments in rare disease research, rising demand for long-term therapeutic solutions, expansion of personalized medicine approaches, increased government support for orphan drugs, advancements in biologic manufacturing technologies. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, growing focus on rare disease treatment accessibility, expansion of specialized infusion-based therapies, rising emphasis on long-term disease management solutions, enhanced focus on patient-centric treatment protocols.

Global Naglazyme Market Segmentation

1) By Indication: Treatment Of Maroteaux-Lamy Syndrome, Other Rare Lysosomal Storage Disorders 2) By Age Group: Pediatric Patients, Adult Patients 3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies, Government And Public Health Programs 4) By End User: Hospitals, Specialty Clinics, Research Institutions, Homecare Settings

What Are The Drivers Of The Naglazyme Market?

The increasing incidence of rare genetic disorders is expected to drive the growth of the naglazyme market going forward. Rare genetic disorders are uncommon inherited conditions resulting from gene mutations, impacting only a small portion of the population. The increasing incidence of rare genetic disorders can be attributed to genetic mutations, improved genetic testing, and population growth. Naglazyme, an enzyme replacement therapy, helps patients with rare genetic disorders such as mucopolysaccharidosis VI (MPS VI) by breaking down and reducing the accumulation of glycosaminoglycans (GAGs), thereby improving mobility, respiratory function, and overall quality of life. For instance, in October 2024, according to Cystic Fibrosis Trust, a UK-based charity dedicated to supporting people with cystic fibrosis, in 2022, around 11,148 cystic fibrosis (a genetic disorder) patients were registered, and this number grew to 11,318 in 2023, reflecting a 1.5% increase in patient registrations year over year. Therefore, the increasing incidence of rare genetic disorders is driving the growth of the naglazyme industry. The rising adoption of personalized medicine is expected to propel the growth of the naglazyme market going forward. Personalized medicine involves customizing medical treatment based on an individual's genetic profile, lifestyle, and environment for more effective outcomes. The rising adoption of personalized medicine is driven by several factors, such as advancements in genomic research, improved diagnostic tools, and the growing demand for more targeted and effective treatments. Personalized medicine supports naglazyme by tailoring treatment plans based on an individual's genetic profile and specific disease characteristics, optimizing the efficacy of enzyme replacement therapy for patients with rare genetic disorders like mucopolysaccharidosis VI (MPS VI), ensuring more precise and effective management of the condition. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the rising adoption of personalized medicine is driving the growth of the naglazyme industry. The rise in healthcare spending is expected to propel the growth of the naglazyme market going forward. Healthcare spending refers to the total expenditure on health services and products, including medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs, to maintain or improve the health and well-being of individuals and populations. Healthcare spending is attributed to an aging population, advancements in medical technology, rising prevalence of chronic diseases, and increased demand for healthcare services. Healthcare expenditure supports Naglazyme by providing the necessary funding for the development, distribution, and accessibility of specialized treatments like enzyme replacement therapy, ensuring that patients with rare genetic disorders such as mucopolysaccharidosis VI (MPS VI) receive the vital care they need to improve their quality of life. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare spending is driving the growth of the naglazyme industry.

Key Players In The Global Naglazyme Market

Major companies operating in the naglazyme market are BioMarin Pharmaceutical Inc.

Regional Insights

North America was the largest region in the naglazyme market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Naglazyme Market?

The naglazyme market consists of sales of injectable solution and lyophilized powder. Values in this market are ‘factory gate’ values, which represent the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Naglazyme Market Report 2026?

The naglazyme market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the naglazyme industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.